Interview: Ernest Bartosik, Country Manager, Unipharm, Poland
Unipharm Poland’s country manager explains what is needed to become a successful OTC and dietary supplement company in Poland, saying that it is “key to master the marketing mix but…
Unipharm is an American pharmaceutical company specializing in the development and marketing of quality over-the-counter (OTC) drugs and nutritional products. Since it was established in the USA in 1992, the Company has consistently grown, and continues to provide award-winning, quality products to its loyal customers in many different countries.
Unipharm has been for many years registered with the US Food and Drug Administration. All of Unipharm’s products are made in the USA under extensive quality control supervision at well-established facilities that follow Good Manufacturing Practice (GMP) guidelines and United States Pharmacopeia (USP) standards. We are also proud to be certified by National Sanitation Foundation (NSF) International. In addition, our products are manufactured, tested and packaged according to regulations mandated by every country the Company sells in.
The world headquarters of Unipharm is located here in the Empire State Building in New York City, and there are many branch offices worldwide. Unipharm products are successful, both in terms of brand awareness and sales, and this is demonstrated by the kind of loyalty that you, our loyal customers, demonstrate to us. The Company is committed to continue offering a wide variety of quality goods that are both safe and effective.
In Poland Unipharm’s offer is dedicated to physicians, their patients, and consumers in area of joint care, bone health, osteoporosis, beauty, aging, memory loss and immune support. The Company is deeply engaged in both health education and activities which support healthy life, medical prophylaxis and treatment.
Unipharm Poland’s country manager explains what is needed to become a successful OTC and dietary supplement company in Poland, saying that it is “key to master the marketing mix but…
Maciej Wieczorek, president of Celon Pharma, discusses the award-winning success of the 2016 IPO on the Warsaw stock exchange and the opportunities this has opened up, as well as investment…
Iwona Skrzekowska-Baran, owner and CEO of Pharm&Med, a young, exciting Polish consultancy that is helping clients to transform evidence, policy insights, and market intelligence into effective market access strategies. She…
Leonardo Maffioli, senior marketing and commercial manager of the fertility and endocrinology division of IBSA, discusses the story of IBSA Poland and the potential of the Polish market for the…
Jacek Glinka, president of Mylan Europe, and Tomasz Buczek, country manager of Mylan Poland, discuss the intricate dynamics of the European and Polish pharmaceutical ecosystem and the steps required to…
Witold Włodarczyk, director general of Polmed (Polish chamber for medical devices), discusses the Polish medical device landscape and the policy surrounding the sector, especially the proposed 2016 reimbursement act. Furthermore,…
Krzysztof Łokaj, general manager of Chiesi Poland, discusses the positioning of the company as they become the absolute leaders in the respiratory field, driven by Fostex® and soon Trimbow®. Furthermore,…
Dariusz Głogowski, country manager of Alvogen Poland, discusses his successful strategy to introduce biosimilars onto the Polish market and the nation’s moves to reward this new wave of generics. Furthermore,…
Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way.…
Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better…
Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the…
Mieczysław Wośko, president and founder of Polfarmex, a leading Polish company, discusses the key factors behind the enterprise’s successful growth and the movement towards R&D to create their own treatments.…
Michał Mieszkowski, general manager of Angelini Poland, discusses the strategic significance of Poland for the company, as the third largest affiliate within the global company, the company’s impressive product portfolio…
See our Cookie Privacy Policy Here
